Is ABBV a good stock to buy right now?

Based on our 6-factor quantitative model, AbbVie Inc. (ABBV) receives a "Reduce" rating with a composite score of 45.8/100. It is ranked #2,148 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 52/100, Momentum 41/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for ABBV?

AbbVie Inc. (ABBV) has a "Reduce" rating and 2-star score. The composite score of 45.8 ranks it #2,148 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is ABBV in?

AbbVie Inc. operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $380.25 billion. It is classified as a mega-cap stock.

Does ABBV pay a dividend?

Yes, ABBV pays a dividend with a current yield of 2.81%. For every $1,000 invested, you would receive approximately $28.10 in annual dividend income.

What is ABBV's P/E ratio?

ABBV has a trailing P/E ratio of 91.67x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is ABBV?

ABBV's quality factor score is 50/100. Gross margin: 69.8%. ROE: 91.1% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is ABBV valued compared to peers?

ABBV's value factor score is 52/100 (higher = cheaper). Key multiples: P/E 91.7x, EV/EBITDA 29.9x. Valuation is roughly in line with peers.

What is ABBV's debt level?

ABBV's debt-to-equity ratio is -2645%. Sector average: 32%. Low leverage suggests conservative financial management.

ABBV has a beta of 0.44, meaning it is less volatile than the market. Stability score: 82/100.

Does ABBV have high short interest?

ABBV's short interest factor score is 17/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

ABBV Stock Analysis: Reduce (Score 45.8/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
ABBV	-2.10%	-0.43%	-8.40%	-8.99%	+19.37%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-2.03%	-4.03%	-8.74%	-8.63%	-10.16%	-	-	-
Alpha vs Sector	-0.75%	-0.77%	-4.59%	-4.16%	+10.16%	-	-	-

Metric	ABBV	Benchmark
P/E Ratio	91.7x	+288%
EV/EBITDA	29.9x	+372%
Price / Book	83.5x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
ABBV AbbVie Inc.	46	50	52	41	91.7x	91.1%	69.8%	6.9%	9.1%	-2,645.0x	$380.2B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.7%	0.7%	0.7%	0.6%	0.7%	0.7%	0.6%	0.8%	0.8%	0.8%	0.8%
Operating Margin %	0.2%	0.2%	0.2%	0.2%	0.3%	0.3%	0.2%	0.4%	0.2%	0.3%	0.4%
EBITDA Margin %	0.2%	0.2%	0.3%	0.2%	0.3%	0.3%	0.3%	0.4%	0.2%	0.4%	0.4%
Net Margin %	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.2%	0.2%	0.2%	0.2%
FCF Margin %	16.8%	-	31.7%	-	-	-	36.7%	38.4%	39.0%	33.4%	1.2%
ROE %	-123.4%	-131.1%	1.3%	0.5%	0.7%	0.7%	0.4%	-96.5%	-67.3%	1.0%	1.3%
ROA %	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%
ROIC %	0.2%	19.4%	11.1%	14.5%	17.8%	15.5%	9.9%	55.0%	12.9%	15.5%	16.6%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.7%

0.6%

0.7%

0.6%

0.8%

Operating Margin %

0.2%

0.3%

0.2%

0.4%

0.2%

0.3%

0.4%

EBITDA Margin %

0.2%

0.3%

0.2%

0.3%

0.4%

0.2%

0.4%

Net Margin %

0.1%

0.2%

0.1%

0.2%

FCF Margin %

16.8%

31.7%

36.7%

38.4%

39.0%

33.4%

1.2%

ROE %

-123.4%

-131.1%

1.3%

0.5%

0.7%

0.4%

-96.5%

-67.3%

1.0%

1.3%

ROA %

0.0%

0.1%

0.0%

0.1%

ROIC %

0.2%

19.4%

11.1%

14.5%

17.8%

15.5%

9.9%

55.0%

12.9%

15.5%

16.6%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$59.0B	$61.2B	$56.3B	$54.3B	$58.1B	$56.2B	$45.8B	$33.3B	$32.8B	$28.2B	$25.6B	$22.9B
	—	$18.2B	—	$20.4B	$17.4B	$17.4B	—	—	—	—	—	—
	$41.1B	$43.0B	$39.4B	$33.9B	$40.6B	$38.8B	$30.4B	$25.8B	$25.0B	$21.2B	$19.8B	$18.4B
Gross Margin	69.8%	70.2%	70.0%	62.4%	70.0%	69.0%	63.4%	77.6%	76.4%	75.0%	77.3%	80.3%
	—	$14.0B	—	$12.9B	$15.3B	$12.3B	—	—	—	—	—	—
Research & Development	—	—	$12.8B	—	—	—	$7.8B	$6.8B	$10.8B	$5.3B	$4.6B	$4.4B
Depreciation	—	—	$8.4B	—	—	—	$6.5B	$2.0B	$1.8B	$1.5B	$1.2B	$836M
Total Operating Expenses	—	$27.9B	—	$21.1B	$22.5B	$20.8B	—	—	—	—	—	—
	$14.4B	$15.1B	$9.1B	$12.8B	$18.1B	$17.9B	$11.4B	$13.0B	$6.4B	$9.5B	$9.4B	$7.5B
EBIT	$14.4B	$15.1B	$9.1B	$12.8B	$18.1B	$17.9B	$11.4B	$13.0B	$6.4B	$9.5B	$9.4B	$7.5B
EBITDA	$14.4B	$15.1B	$14.3B	$12.8B	$18.1B	$17.9B	$12.1B	$12.0B	$8.1B	$10.2B	$10.0B	$8.2B
Operating Margin	24.6%	24.6%	16.2%	23.5%	31.2%	31.9%	24.8%	39.0%	19.5%	33.8%	36.4%	33.0%
EBITDA Margin	24.3%	24.6%	25.3%	23.5%	31.2%	31.9%	26.5%	35.9%	24.7%	36.3%	39.2%	35.7%
	—	$2.9B	—	$2.2B	$2.2B	$2.4B	—	—	—	—	—	—
	—	$6.6B	—	$6.3B	$13.5B	$13.0B	—	—	—	—	—	—
Income Tax Expense	—	$2.4B	-$570M	$1.4B	$1.6B	$1.4B	-$1.2B	$544M	-$490M	$2.4B	$1.9B	$1.5B
	$4.0B	$4.2B	$4.3B	$4.9B	$11.8B	$11.5B	$4.6B	$7.9B	$5.7B	$5.3B	$6.0B	$5.1B
Net Margin	6.9%	6.9%	7.6%	9.0%	20.4%	20.5%	10.1%	23.7%	17.4%	18.8%	23.2%	22.5%
	$2.37	$2.37	$2.40	$2.73	$6.65	$6.48	$2.73	$5.30	$3.67	$3.31	$3.65	$3.15
Diluted EPS	$2.37	$2.36	$2.40	$2.72	$6.63	$6.45	$2.73	$5.30	$3.67	$3.31	$3.65	$3.15
Weighted Avg Basic	—	1.8B	—	1.8B	1.8B	1.8B	—	—	—	—	—	—
Weighted Avg Diluted	—	1.8B	—	1.8B	1.8B	1.8B	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$59.0B

$61.2B

$56.3B

$54.3B

$58.1B

$56.2B

$45.8B

$33.3B

$32.8B

$28.2B

$25.6B

$22.9B

—

$18.2B

—

$20.4B

$17.4B

—

$41.1B

$43.0B

$39.4B

$33.9B

$40.6B

$38.8B

$30.4B

$25.8B

$25.0B

$21.2B

$19.8B

$18.4B

Gross Margin

69.8%

70.2%

70.0%

62.4%

70.0%

69.0%

63.4%

77.6%

76.4%

75.0%

77.3%

80.3%

—

$14.0B

—

$12.9B

$15.3B

$12.3B

—

Research & Development

—

$12.8B

—

$7.8B

$6.8B

$10.8B

$5.3B

$4.6B

$4.4B

Depreciation

—

$8.4B

—

$6.5B

$2.0B

$1.8B

$1.5B

$1.2B

$836M

Total Operating Expenses

—

$27.9B

—

$21.1B

$22.5B

$20.8B

—

$14.4B

$15.1B

$9.1B

$12.8B

$18.1B

$17.9B

$11.4B

$13.0B

$6.4B

$9.5B

$9.4B

$7.5B

EBIT

$14.4B

$15.1B

$9.1B

$12.8B

$18.1B

$17.9B

$11.4B

$13.0B

$6.4B

$9.5B

$9.4B

$7.5B

EBITDA

$14.4B

$15.1B

$14.3B

$12.8B

$18.1B

$17.9B

$12.1B

$12.0B

$8.1B

$10.2B

$10.0B

$8.2B

Operating Margin

24.6%

16.2%

23.5%

31.2%

31.9%

24.8%

39.0%

19.5%

33.8%

36.4%

33.0%

EBITDA Margin

24.3%

24.6%

25.3%

23.5%

31.2%

31.9%

26.5%

35.9%

24.7%

36.3%

39.2%

35.7%

—

$2.9B

—

$2.2B

$2.4B

—

$6.6B

—

$6.3B

$13.5B

$13.0B

—

Income Tax Expense

—

$2.4B

-$570M

$1.4B

$1.6B

$1.4B

-$1.2B

$544M

-$490M

$2.4B

$1.9B

$1.5B

$4.0B

$4.2B

$4.3B

$4.9B

$11.8B

$11.5B

$4.6B

$7.9B

$5.7B

$5.3B

$6.0B

$5.1B

Net Margin

6.9%

7.6%

9.0%

20.4%

20.5%

10.1%

23.7%

17.4%

18.8%

23.2%

22.5%

$2.37

$2.40

$2.73

$6.65

$6.48

$2.73

$5.30

$3.67

$3.31

$3.65

$3.15

Diluted EPS

$2.37

$2.36

$2.40

$2.72

$6.63

$6.45

$2.73

$5.30

$3.67

$3.31

$3.65

$3.15

Weighted Avg Basic

—

1.8B

—

1.8B

—

Weighted Avg Diluted

—

1.8B

—

1.8B

—

AbbVie Inc. (ABBV) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does AbbVie Inc. Do?

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. AbbVie Inc. (ABBV) is classified as a mega-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Richard A. Gonzalez and employs approximately 50,000 people, headquartered in North Chicago, Illinois. With a market capitalization of $380.2B, ABBV is one of the largest companies in the Healthcare sector.

AbbVie Inc. (ABBV) Stock Rating — Reduce (April 2026)

As of April 2026, AbbVie Inc. receives a Reduce rating with a composite score of 45.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ABBV ranks #2,148 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AbbVie Inc. ranks #245 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ABBV Stock Price and 52-Week Range

AbbVie Inc. (ABBV) currently trades at $212.40. The 52-week high for ABBV is $244.81, which means the stock is currently trading -13.2% from its annual peak. The 52-week low is $164.39, putting the stock 29.2% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is ABBV Overvalued or Undervalued? — Valuation Analysis

AbbVie Inc. (ABBV) carries a value factor score of 52/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 91.67x, compared to the Healthcare sector average of 23.63x — a premium of 288%. The price-to-sales ratio is 6.19x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ABBV trades at 29.91x EV/EBITDA, versus 6.34x for the sector.

Overall, ABBV's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

AbbVie Inc. Profitability — ROE, Margins, and Quality Score

AbbVie Inc. (ABBV) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 91.1%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 3.0% versus the sector average of -33.1%.

On a margin basis, AbbVie Inc. reports gross margins of 69.8%, compared to 71.5% for the sector. The operating margin is 24.6% (sector: -66.1%). Net profit margin stands at 6.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 9.1% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

ABBV Debt, Balance Sheet, and Financial Health

AbbVie Inc. has a debt-to-equity ratio of -2645.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.67x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $64.50B. Cash and equivalents stand at $5.63B.

ABBV has a beta of 0.44, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for AbbVie Inc. is 82/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

AbbVie Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AbbVie Inc. reported revenue of $59.00B and earnings per share (EPS) of $2.37. Net income for the quarter was $3.98B. Gross margin was 69.8%. Operating income came in at $14.36B.

In FY 2025, AbbVie Inc. reported revenue of $61.16B and earnings per share (EPS) of $2.37. Net income for the quarter was $4.23B. Gross margin was 70.2%. Revenue grew 8.6% year-over-year compared to FY 2024. Operating income came in at $15.07B.

In Q3 2025, AbbVie Inc. reported revenue of $15.78B and earnings per share (EPS) of $0.10. Net income for the quarter was $188M. Gross margin was 66.4%. Revenue grew 9.1% year-over-year compared to Q3 2024. Operating income came in at $1.90B.

In Q2 2025, AbbVie Inc. reported revenue of $15.42B and earnings per share (EPS) of $0.52. Net income for the quarter was $941M. Gross margin was 71.8%. Revenue grew 6.6% year-over-year compared to Q2 2024. Operating income came in at $4.89B.

Over the past 8 quarters, AbbVie Inc. has demonstrated a growth trajectory, with revenue expanding from $14.46B to $59.00B. Investors analyzing ABBV stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ABBV Dividend Yield and Income Analysis

AbbVie Inc. (ABBV) currently pays a dividend yield of 2.8%. At this yield, a $10,000 investment in ABBV stock would generate approximately $$281.00 in annual dividend income. The net margin of 6.9% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

ABBV Momentum and Technical Analysis Profile

AbbVie Inc. (ABBV) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 17/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ABBV vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AbbVie Inc. (ABBV) ranks #245 out of 838 stocks based on the Blank Capital composite score. This places ABBV in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ABBV against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ABBV vs S&P 500 (SPY) comparison to assess how AbbVie Inc. stacks up against the broader market across all factor dimensions.

ABBV Next Earnings Date

No upcoming earnings date has been announced for AbbVie Inc. (ABBV) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ABBV? — Investment Thesis Summary

The quantitative profile for AbbVie Inc. suggests caution. Low volatility (stability score 82/100) reduces downside risk.

In summary, AbbVie Inc. (ABBV) earns a Reduce rating with a composite score of 45.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ABBV stock.

Related Resources for ABBV Investors

Explore more research and tools: ABBV vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ABBV head-to-head with peers: ABBV vs AZN, ABBV vs SLGL, ABBV vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

How AbbVie’s Dermatology Data Push and Humira Discount Strategy Will Impact AbbVie (ABBV) Investors

Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?

Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead

This Startup’s Psoriasis Drug Studies Have Lifted Its Stock

Sector Update: Health Care Stocks Fall Late Afternoon

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

AbbVie Inc. (ABBV) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does AbbVie Inc. Do?

AbbVie Inc. (ABBV) Stock Rating — Reduce (April 2026)

ABBV Stock Price and 52-Week Range

Is ABBV Overvalued or Undervalued? — Valuation Analysis

AbbVie Inc. Profitability — ROE, Margins, and Quality Score

ABBV Debt, Balance Sheet, and Financial Health

AbbVie Inc. Revenue and Earnings History — Quarterly Trend

ABBV Dividend Yield and Income Analysis

ABBV Momentum and Technical Analysis Profile

ABBV vs Competitors — Healthcare Sector Ranking and Peer Comparison

ABBV Next Earnings Date

Should You Buy ABBV? — Investment Thesis Summary

Related Resources for ABBV Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

How AbbVie’s Dermatology Data Push and Humira Discount Strategy Will Impact AbbVie (ABBV) Investors

Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?

Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead

This Startup’s Psoriasis Drug Studies Have Lifted Its Stock

Sector Update: Health Care Stocks Fall Late Afternoon